Breaking News Instant updates and real-time market news.

TEVA

Teva

$20.40

0.03 (0.15%)

11:11
05/15/18
05/15
11:11
05/15/18
11:11

Teva reports publication of Phase III HALO study data in JAMA

Teva announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly and monthly subcutaneous dosing regimens of fremanezumab for the prevention of episodic migraine. These pivotal data were published online by The Journal of the American Medical Association. The study evaluated the use of both quarterly and monthly dosing regimens of subcutaneous fremanezumab, compared with placebo in patients with EM who had previously failed multiple medication classes. The HALO EM trial met its primary endpoint demonstrating that fremanezumab significantly reduced monthly migraine days for both quarterly and monthly dosing regimens: The baseline mean number of monthly migraine days was 8.9, 9.2, and 9.1 days in the monthly dosing, quarterly dosing, and placebo groups, respectively. During the 12-week period after the first dose, fremanezumab treatment significantly reduced monthly migraine days to 4.6 days for monthly and 4.9 days for quarterly dosing compared with 5.9 days for placebo. Response rates of greater than or equal to 50% reduction in monthly average number of migraine days were also significantly greater in monthly and quarterly dosing compared with placebo. Additionally, the baseline mean number of monthly days of any acute headache medication use was 7.7, 7.9, and 7.7 days in the monthly, quarterly, and placebo groups, respectively. Fremanezumab significantly reduced monthly days of any acute headache medication use to 4.5 days for monthly and 4.6 days for quarterly dosing compared with 5.4 days for placebo. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled 875 patients and consisted of a screening visit, 28-day pre-treatment period, 12-week treatment period, and final evaluation at week 12. The most common adverse events in patients treated with fremanezumab were injection site pain, induration, and erythema.

  • 15

    May

  • 18

    May

  • 05

    Jun

  • 16

    Jun

TEVA Teva
$20.40

0.03 (0.15%)

04/27/18
JEFF
04/27/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine's Ingrezza can beat Q1 estimates, says Jefferies
Jefferies analyst Biren Amin says his firm's fifth proprietary survey on tardive dyskinesia reaffirms that Neurocrine Biosciences' (NBIX) Ingrezza is leading Teva's (TEVA) Austedo in market share for both moderate-severe and mild cases. The analyst thinks Ingrezza can modestly beat consensus estimates for Q1. He keeps a Buy rating on Neurocrine shares with a $105 price target.
04/30/18
DBAB
04/30/18
NO CHANGE
Target $22
DBAB
Buy
Deutsche raises Valeant price target on extended Xifaxan exclusivity
The stay in the Xifaxan litigation between Valeant Pharmaceuticals (VRX) and Teva (TEVA) was recently extended to July 30, 2018 from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note. According to the court docket, the companies agreed to extend the stay "because the facts and circumstances that warranted a stay as of May 15, 2017 have not materially changed," Gilbert adds. He previously modeled Xifaxan exclusivity through 2024, but pushed that out one more year saying Teva "does not yet appear to have clarity on the path forward for its generic filing." The exclusivity extension to 2025 on Valeant's largest product pushes the analyst's price target for the shares to $22 from $20. The stock in midday trading is up 19c to $18.26. Gilbert looks forward to an update from Teva when the company reports on May 3 and continues to like the risk/reward for Valeant. He keeps a Buy rating on the shares.
05/03/18
WELS
05/03/18
NO CHANGE
Target $16.5
WELS
Underperform
Teva Q1 'just what investors wanted,' says Wells Fargo
Wells Fargo analyst David Maris believes this quarter is exactly the quarter investors wanted out of Teva, namely progress on the cost cutting and raised guidance on the back of a business that is still facing a significant decline given a tough U.S. generics environment and generic Copaxone pressures. The analyst reiterates an Underperform rating and $16.50 price target on the shares.
05/07/18
FBCO
05/07/18
NO CHANGE
Target $23
FBCO
Outperform
Teva turnaround story appears generally on track, says Credit Suisse
Credit Suisse analyst Vamil Divan believes Teva's Q1 earnings were "solid" and sees his bullish thesis on the company as being on track. The analyst notes that the company's restructuring program is proceeding in line with its prior guidance and his expectations, if even a bit ahead of schedule. Divan reiterates an Outperform rating and $23 price target on the shares.

TODAY'S FREE FLY STORIES

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

LNC

Lincoln National

$68.89

-0.555 (-0.80%)

16:24
05/25/18
05/25
16:24
05/25/18
16:24
Syndicate
Breaking Syndicate news story on Lincoln National »

Lincoln National files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGLY

Digital Ally

$2.63

0.075 (2.94%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Digital Ally »

Digital Ally files $25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNGX

Soligenix

$1.58

-0.005 (-0.32%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$35.34

0.08 (0.23%)

16:21
05/25/18
05/25
16:21
05/25/18
16:21
Hot Stocks
HFF Inc. announces $640M sale of 5 Bryant Park office tower in Manhattan »

HFF announces the $640M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/25/18
05/25
16:20
05/25/18
16:20
Options
Closing CBOE SPX and VIX Index summary for May 25th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMED

OncoMed

$2.81

0.06 (2.18%)

16:19
05/25/18
05/25
16:19
05/25/18
16:19
Syndicate
Breaking Syndicate news story on OncoMed »

OncoMed files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTEM

Molecular Templates

$7.02

0.34 (5.09%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Syndicate
Breaking Syndicate news story on Molecular Templates »

Molecular Templates files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

, USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.1K…

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

GLD

SPDR Gold Trust

$123.21

-0.4 (-0.32%)

FXE

Euro Currency Trust

$111.98

-0.62 (-0.55%)

FXC

CurrencyShares Canadian Dollar Trust

$76.07

-0.37 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.20

0.1 (0.10%)

16:15
05/25/18
05/25
16:15
05/25/18
16:15
Periodicals
Disney cuts opening weekend sales forecast for 'Solo', Bloomberg says »

Disney cut its domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMSA

Fairmount Santrol

$5.51

-0.26 (-4.51%)

16:11
05/25/18
05/25
16:11
05/25/18
16:11
Hot Stocks
Fairmount Santrol, Unimin receive final merger approval »

Fairmount Santrol and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBL

RumbleON

$4.88

0.16 (3.39%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on RumbleON »

RumbleON files $20M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$2.25

0.04 (1.81%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on Ageagle Aerial Systems »

Ageagle Aerial Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$0.82

(0.00%)

16:08
05/25/18
05/25
16:08
05/25/18
16:08
Hot Stocks
Appliance Recycling receives noncompliance notice from NASDAQ »

Appliance Recycling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$51.62

-1.13 (-2.14%)

16:06
05/25/18
05/25
16:06
05/25/18
16:06
Hot Stocks
CIT Group names Marisa Harney chief risk officer »

CIT Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.81

(0.00%)

16:04
05/25/18
05/25
16:04
05/25/18
16:04
Hot Stocks
Breaking Hot Stocks news story on Trivago »

Par Investment Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGLN

Magellan Health

$90.05

1.1 (1.24%)

15:56
05/25/18
05/25
15:56
05/25/18
15:56
Hot Stocks
Magellan Health boosts stock repurchase authorization to $400M »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

LPI

Laredo Petroleum

$8.60

-0.765 (-8.17%)

15:50
05/25/18
05/25
15:50
05/25/18
15:50
Options
Notable put spread in Laredo Petroleum on a rough week for shares »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.57

-0.025 (-0.17%)

15:42
05/25/18
05/25
15:42
05/25/18
15:42
Periodicals
GE lighting business, pursued by multiple suitors, could fetch $1B, FBN says »

Charles Gasparino of Fox…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$37.03

0.15 (0.41%)

15:40
05/25/18
05/25
15:40
05/25/18
15:40
Options
AstraZeneca call buyer opens position 4% above spot »

AstraZeneca call buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

HEDJ

WisdomTree Europe Hedged Equity Fund

$66.46

-0.24 (-0.36%)

15:30
05/25/18
05/25
15:30
05/25/18
15:30
Options
Wisdom Tree Europe Hedged Equity Fund attracts put buying »

Wisdom Tree Europe Hedged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

$18.43

-0.12 (-0.65%)

15:29
05/25/18
05/25
15:29
05/25/18
15:29
Conference/Events
Altice USA management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.